Tue, 19 May 2026
Hunch
Market30 Jun 2026

Will Anthropic name a Claude Science pharma/biotech partner by 10 Aug 2026?

BinaryResolves 10 Aug 2026
Hunch47%
Your forecast
  • Yes
  • No
Resolved
Resolved: NO

Anthropic’s newsroom, the designated source of truth, named no Claude Science pharma or biotech partner by 10 August; the 4 August Icon clinical-trials deal was announced by Icon, not Anthropic (anthropic.com; Fierce Biotech).

Resolved 10 Aug 2026
How this resolves

Partnership market resolves YES only on an official Anthropic announcement naming a specific pharma or biotech partner; Anthropic's newsroom is the source of truth.

The pattern behind it

1 of 4
Of these four flagship AI-in-science efforts, one reached a positive mid-stage clinical readout, one failed in the clinic, one produced a research platform rather than a drug, and one was discontinued. The pattern is genuinely split: strong tooling wins are common, near-term clinical payoffs are not.

AI has often sped up the early stages of drug discovery. It has not yet changed the fact that roughly nine in ten drugs fail in clinical trials. We looked at four big AI science efforts. The record of AI-made drugs is split: real scientific progress, and trials that stalled all the same.